Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 79 Return-on-Tangible-Asset is 0.79% as of Mar. 2026, which is 79% below its 10-year median of 3.76. GuruFocus rates CHIX:BAVAC with a GF Score™ of 79/100 and a GF Value™ of kr164.93. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Bavarian Nordic AS ranks better than 92.8% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bavarian Nordic AS's annualizedNet Income for the quarter that ended in Mar. 2026 was kr68 Mil. Bavarian Nordic AS's average total tangible assets for the quarter that ended in Mar. 2026 was kr8,610 Mil. Therefore, Bavarian Nordic AS's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.79%.
The historical rank and industry rank for Bavarian Nordic AS's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:BAVAc'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -15.11 Med: 3.76 Max: 20.6
Current: 14.16
During the past 13 years, Bavarian Nordic AS's highest Return-on-Tangible-Asset was 20.60%. The lowest was -15.11%. And the median was 3.76%.
CHIX:BAVAc's Return-on-Tangible-Asset is ranked better than 92.8% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs CHIX:BAVAc: 14.16
Bavarian Nordic AS (CHIX:BAVAc) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bavarian Nordic AS Return-on-Tangible-Asset Related Terms
Bavarian Nordic AS Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.79% mean?
Bavarian Nordic AS (CHIX:BAVAC) has a Return-on-Tangible-Asset of 0.79% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bavarian Nordic AS and its competitors. This is 79% below median its historical median of 3.76. According to the industry distribution chart, Bavarian Nordic AS ranks #102 out of 1416 companies in the Biotechnology industry, placing it in the top 7.2%.
Is Bavarian Nordic AS's Return-on-Tangible-Asset too high?
Bavarian Nordic AS's current Return-on-Tangible-Asset of 0.79% is 79% below median its 10-year median of 3.76. Based on the distribution chart, Bavarian Nordic AS ranks #102 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #102 out of 1416 companies for Return-on-Tangible-Asset. This places Bavarian Nordic AS in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bavarian Nordic AS and its competitors. Bavarian Nordic AS's current Return-on-Tangible-Asset is 0.79%, which is 79% below median its own 10-year median of 3.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Bavarian Nordic AS (CHIX:BAVAC) has a current Return-on-Tangible-Asset of 0.79%. The stock's GF Value™ is kr164.93, compared to a current price of kr188.30 — trading 14.2% above its estimated fair value. The current Return-on-Tangible-Asset is 0.79%, which is 79% below median its 10-year median of 3.76. Bavarian Nordic AS's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Return-on-Tangible-Asset is 0.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 14.2% above its estimated GF Value™ of kr164.93.
Key valuation signals for CHIX:BAVAC:
Return-on-Tangible-Asset: 0.79% (79% below median its 10-year median of 3.76)
GF Value™: kr164.93 vs. price of kr188.30 (14.2% above fair value)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
79GF Score
Get the complete analysis for CHIX:BAVAC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
